Healthcare

Is Partnership-Led Innovation Replacing M&A in Oncology? BMS and Janux Strike $850 Million T-Cell Engager Deal

22 January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Janux Therapeutics,…

ByByAnuja Singh Jan 24, 2026

Is Strategic Out-Licensing the Fastest Path to Global Scale? Restari Secures $230 Million PDE-5 Deal with AriBio

23 January 2026 Executive Summary Restari has secured exclusive global out-licensing rights from AriBio for a next-generation PDE-5…

ByByAnuja Singh Jan 24, 2026

Is GSK Buying Its Way Past the Patent Cliff? $2.2 Billion Rapt Therapeutics Deal Signals Pipeline Reset

January 2026 Executive Summary GSK has agreed to acquire Rapt Therapeutics, a U.S.-based biotech focused on inflammatory and…

ByByAnuja Singh Jan 24, 2026

Is AI Poised to Replace the Traditional Drug Discovery Lab? Nvidia CEO Signals a Paradigm Shift in Pharma R&D

23 January 2026 Executive Summary Nvidia CEO Jensen Huang has underscored the transformative potential of artificial intelligence in…

ByByAnuja Singh Jan 24, 2026
Image Not Found

BioNextAI Media Report: Merck-Mayo Clinic AI Pact—5 Petabytes of Data to Slash Drug Timelines 30-50% Amid R&D Arms Race

Published by BioNextAI Media – Merck has forged a high-octane research collaboration with Mayo Clinic, fusing 5 petabytes of…

ByByAnuja Singh Mar 2, 2026

BioNextAI Media Report: Keytruda’s Ovarian Cancer Combo Triumph—28% Survival Boost Lifts Merck Stock 4% Amid Patent Shadow

Published by BioNextAI Media – Merck’s KEYTRUDA (pembrolizumab) delivered compelling Phase 3 data from combination regimens in ovarian cancer,…

ByByAnuja Singh Mar 2, 2026
Scroll to Top